Thesis
COMP360's Phase 3 TRD win sets up a first-in-class psilocybin NDA; FDA approval and commercial execution are the remaining tests
COMP360 is a psilocybin-based therapy targeting treatment-resistant depression in patients who have failed conventional antidepressants. The thesis turns on FDA approval of the NDA following COMP006 26-week data, with a clean label that enables scalable administration. The primary risk is a restrictive REMS or label requiring supervised administration infrastructure that limits commercial reach, with esketamine (Spravato) already entrenched in the TRD setting as the standard of care comparator.
Focus
NDA submission for COMP360 in TRD
Q4 2026
Bull
A complete NDA submission in Q4 2026 incorporating the COMP006 26-week Part B durability data would trigger formal FDA acceptance and initiate the accelerated CNPV-assisted review, placing COMP360 on a clear path to a first-in-class psilocybin approval in TRD. A clean submission with no refuse-to-file action would validate the totality of the Phase 3 data package — efficacy from COMP005 and COMP006, safety across 1,000+ participants, and long-term durability — and would materially de-risk the remaining approval step.
Bear
The most likely failure mode is a delay or deficiency in the COMP006 26-week Part B data readout that prevents timely NDA completion, pushing the submission past Q4 2026 and eroding the CNPV timeline advantage. A second risk is an FDA refuse-to-file action citing inadequacies in the chemistry, manufacturing, and controls section or the novel psilocybin-assisted therapy delivery model, which would require additional data generation and restructuring of the submission package.
Unlock the full thesis for CMPS.
The living thesis log, full pipeline, competitive landscape, and the ability to ask anything — updated automatically as the story changes.
Start your 7-day free trialRelated companies
Generated automatically from SEC filings, trial readouts, and earnings calls. For informational purposes only. Not financial advice.